Decades after cisplatin's approval, platinum-based chemotherapy continues to anchor treatment regimens across tumor types, new research finds.
|Videos|December 19, 2019
Less Than 50% of Candidates Receive Genetic Testing - Here's Why
Banu Arun, MD, explains the various reasons for the lack of genetic testing in appropriate candidates. This video was filmed December 12 at the 2019 San Antonio Breast Cancer Symposium.
Advertisement
Banu Arun, MD, explains the various reasons for the lack of genetic testing in appropriate candidates. This video was filmed December 12 at the 2019 San Antonio Breast Cancer Symposium.
Banu Arun, MD: Studies have shown that less than 50%—even less than 30%—of eligible patients actually are referred for genetic counseling and testing. We really don’t know the reasons for that, but I think it’s really multifactorial. It depends on education, patient perception, and maybe simply not having access to simple risk-assessment tools or genetic counselors.
Advertisement
Related to this article
In the phase 2 ZUPREME 1 trial, the once-weekly amylin analog was well tolerated, with nausea mostly mild and limited to dose escalation.
Post hoc STEP UP data at EASD 2026 show liver fat fell from 8.8% to 3.1% at 72 weeks in a 55-person MRI subgroup, though no placebo comparison was reported.
Tor Härnqvist, MD, discusses immune testing after invasive pneumococcal disease, serotype-informed vaccine selection, and pharmacists' role in supporting patients on immunoglobulin therapy.
In adults with type 2 diabetes at high cardiovascular (CV) risk, the oral GLP-1 RA also improved HbA1C and weight, with less hypoglycemia but more GI events.
In an interview with Pharmacy Times, LINKER-SMM1 study investigator Paula Rodríguez-Otero, MD, PhD, a hematologist at Clínica Universidad de Navarra in Pamplona, Spain, explains how researchers selected high-risk patients and how she weighs infections against the potential to prevent progression to active disease.
BRUIN CLL-313 showed significantly longer progression-free survival vs bendamustine plus rituximab, bringing a noncovalent BTK inhibitor to first-line care.
Phase 2b data from EASD 2026 show the amylin-incretin combination also cut HbA1C by up to 2.9% in adults with obesity or overweight and type 2 diabetes.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Semaglutide Normalized Liver Fat in Most Adults With Obesity
2
Reframing Statins and Brain Health Around Stroke Prevention
3
Butter, Beef Tallow, and LDL: Where Dietary Guidelines Diverge
4
Why Patients Fear Statins Will Affect Their Memory
5